- Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.
- GSK gained FDA clearance for a lung cancer medicine, while the FDA began reviewing other highly anticipated drugs.
GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.
2 reports, 1 independent
Updated Aug 28
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
GSK is seeking priority review for its Jemperli application, and the FDA set the PDUFA action date.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA is currently reviewing new drug applications for market entry.
- Future Pak is seeking FDA approval for its product Mytesi to market in the U.S.
- A product was launched in the U.S. market following FDA involvement.
- The FDA is monitoring drug industry practices and pricing, utilizing studies published by JAMA.